Generative AI in Life Sciences, Still In Growth?
Generative AI, a subset of artificial intelligence, has been making waves in various industries, and life sciences is no exception. This technology leverages large language models like GPT-4 to generate new content in diverse forms such as audio, code, images, text, simulations, and videos. The potential of Generative AI in transforming the life sciences industry is immense, from delivering targeted and customized information to stakeholders to improving the productivity of skilled resources like medical writers.
Generative AI in Life Sciences
Generative AI can revolutionize the life sciences industry in several ways. It can transform content forms and be used for content analysis, synthetic data creation, dialogue and response generation, summarization and content translation, and classification and entity identification. The impact of Generative AI on the life sciences industry can be profound, enabling swift decision-making, addressing skill gaps, converting data to intelligence, and delivering insights.
Large language models, such as GPT-3 and GPT-4, can identify and extract information from unstructured text and accurately classify it into suitable domain taxonomies. This capacity for classification and entity identification could have far-reaching applications in various domains, including Safety, Regulatory and Labeling, MLR review, and the marketing and sales of pharmaceutical companies.
Generative AI models can accelerate tasks such as summarizing and synthesizing literature articles and large clinical/regulatory documents when combined with embedding technology and vector databases. It could improve content authoring efficiency throughout the drug lifecycle. Generative AI solutions can also automate the initial draft of translated content, ensuring content availability across local affiliates.
Still a growing concern?
While Generative AI holds great promise, it’s important to be aware of the potential pitfalls. The outputs may not always be accurate or appropriate, and there can be risks of bias and manipulation, leading to reputational and legal risks. The model’s accuracy depends on the quality of the training data and the match between the model and the use case.
Real-World Use Cases of Generative AI in Life Sciences
Generative AI can be a powerful tool in safety and pharmacovigilance. Adverse events must be reported to regulatory authorities, which can be time-consuming and error-prone. Generative AI can help identify and extract relevant information from safety reports, generate a first draft of the adverse event report, and allow the safety professional to review and refine the output.
Generative AI can also play a crucial role in drug discovery by analyzing vast research data, identifying patterns, and suggesting promising drug candidates. It can also be used to cleanse data and create synthetic data to augment datasets while providing recommendations on the next-best action across various medical and sales-related interactions.
MosaicML in Life Sciences
MosaicML allows you to train your own AI model on proprietary data from clinical trials, scientific literature, and molecular databases. This model can discover patterns and relationships between data like protein sequences, biological systems, and disease states. Importantly, MosaicML ensures privacy and regulatory compliance by keeping your workflow in-house, allowing you to maintain full control of your data and total ownership of your AI model.
MosaicML can be used in various areas of life sciences:
Drug Discovery: It can transform the design, optimization, and synthesis of molecules and power the virtual creation of new and lead candidates.
Drug Development: MosaicML can predict drug-protein interactions and determine drug effectiveness once a potential new drug has been identified.
Clinical Trials: It can use chatbots for participant pre-screening, identify latent trends through automated document analysis, and generate synthetic datasets that preserve patient privacy.
Precision Medicine: MosaicML can enable comprehensive genome sequencing and molecular biomarker analysis, and power high-throughput imaging and diagnostics.
MosaicML offers optimized performance, drastically reducing the amount of computation needed to generate high-quality models. It provides maximum scalability, making state-of-the-art deep learning infrastructure available to anyone with a few command lines. It ensures ultimate security, allowing you to train advanced AI models in any cloud environment — or on-prem — with complete data privacy and full model ownership. Lastly, its ease of use, with one-click training and one-click inference, reduces the time needed to develop complex AI models by orders of magnitude.
Conclusion
Generative AI is not a one-time investment. It requires continuous improvement, investment, and updates, which can be expensive. As life sciences companies scale AI, they should look at building foundational teams that understand the implications of data, security, and legal aspects within their ecosystem. With the right approach and careful consideration, Generative AI can revolutionize the life sciences industry, bringing about a new era of innovation and efficiency.
To learn more about Future Tech, make sure to follow.
My Blog — Future technology simplified to read and implement.
My LinkedIn — Short form opinions on future tech.
References
